Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TKMR's Cash to Debt is ranked higher than
83% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. TKMR: No Debt )
TKMR' s 10-Year Cash to Debt Range
Min: 14.07   Max: No Debt
Current: No Debt

Equity to Asset 0.75
TKMR's Equity to Asset is ranked higher than
78% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. TKMR: 0.75 )
TKMR' s 10-Year Equity to Asset Range
Min: -1   Max: 0.93
Current: 0.75

-1
0.93
Interest Coverage No Debt
TKMR's Interest Coverage is ranked higher than
62% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TKMR: No Debt )
TKMR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 6.30
M-Score: 10.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -220.06
TKMR's Operating margin (%) is ranked higher than
65% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. TKMR: -220.06 )
TKMR' s 10-Year Operating margin (%) Range
Min: -22383.33   Max: 16.57
Current: -220.06

-22383.33
16.57
Net-margin (%) -258.36
TKMR's Net-margin (%) is ranked higher than
64% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. TKMR: -258.36 )
TKMR' s 10-Year Net-margin (%) Range
Min: -19172.92   Max: 209.94
Current: -258.36

-19172.92
209.94
ROE (%) -43.09
TKMR's ROE (%) is ranked higher than
68% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. TKMR: -43.09 )
TKMR' s 10-Year ROE (%) Range
Min: -984.09   Max: 127.91
Current: -43.09

-984.09
127.91
ROA (%) -33.34
TKMR's ROA (%) is ranked higher than
68% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. TKMR: -33.34 )
TKMR' s 10-Year ROA (%) Range
Min: -58.63   Max: 146.65
Current: -33.34

-58.63
146.65
ROC (Joel Greenblatt) (%) -2095.22
TKMR's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. TKMR: -2095.22 )
TKMR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2178.98   Max: 249.49
Current: -2095.22

-2178.98
249.49
Revenue Growth (3Y)(%) -14.80
TKMR's Revenue Growth (3Y)(%) is ranked higher than
68% of the 782 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. TKMR: -14.80 )
TKMR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.8   Max: 268.4
Current: -14.8

-29.8
268.4
EBITDA Growth (3Y)(%) 32.10
TKMR's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. TKMR: 32.10 )
TKMR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 40.6
Current: 32.1

0
40.6
EPS Growth (3Y)(%) -100.00
TKMR's EPS Growth (3Y)(%) is ranked higher than
50% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. TKMR: -100.00 )
TKMR' s 10-Year EPS Growth (3Y)(%) Range
Min: -100   Max: 30.8
Current: -100

-100
30.8
» TKMR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

TKMR Guru Trades in Q1 2014

Jim Simons 25,000 sh (New)
Steven Cohen 46,283 sh (New)
» More
Q2 2014

TKMR Guru Trades in Q2 2014

Jim Simons 150,200 sh (+500.80%)
» More
Q3 2014

TKMR Guru Trades in Q3 2014

Paul Tudor Jones 100,000 sh (New)
Jim Simons 22,900 sh (-84.75%)
» More
Q4 2014

TKMR Guru Trades in Q4 2014

Jim Simons 26,700 sh (+16.59%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TKMR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.41
TKMR's Forward P/E is ranked higher than
97% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: 10.41 )
N/A
P/B 4.40
TKMR's P/B is ranked higher than
72% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. TKMR: 4.40 )
TKMR' s 10-Year P/B Range
Min: 0.32   Max: 262.5
Current: 4.4

0.32
262.5
P/S 21.19
TKMR's P/S is ranked higher than
61% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. TKMR: 21.19 )
TKMR' s 10-Year P/S Range
Min: 0.74   Max: 41.37
Current: 21.19

0.74
41.37
EV-to-EBIT -10.17
TKMR's EV-to-EBIT is ranked higher than
66% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: -10.17 )
TKMR' s 10-Year EV-to-EBIT Range
Min: -29.4   Max: 12.8
Current: -10.17

-29.4
12.8
Current Ratio 5.76
TKMR's Current Ratio is ranked higher than
77% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. TKMR: 5.76 )
TKMR' s 10-Year Current Ratio Range
Min: 0.95   Max: 17.09
Current: 5.76

0.95
17.09
Quick Ratio 5.76
TKMR's Quick Ratio is ranked higher than
78% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. TKMR: 5.76 )
TKMR' s 10-Year Quick Ratio Range
Min: 0.95   Max: 17.09
Current: 5.76

0.95
17.09
Days Sales Outstanding 47.96
TKMR's Days Sales Outstanding is ranked higher than
88% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. TKMR: 47.96 )
TKMR' s 10-Year Days Sales Outstanding Range
Min: 2.76   Max: 996.15
Current: 47.96

2.76
996.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.50
TKMR's Price/Net Cash is ranked higher than
88% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 86.70 vs. TKMR: 4.50 )
TKMR' s 10-Year Price/Net Cash Range
Min: 0.38   Max: 38.5
Current: 4.5

0.38
38.5
Price/Net Current Asset Value 4.40
TKMR's Price/Net Current Asset Value is ranked higher than
87% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 39.00 vs. TKMR: 4.40 )
TKMR' s 10-Year Price/Net Current Asset Value Range
Min: 0.36   Max: 6.08
Current: 4.4

0.36
6.08
Price/Tangible Book 4.20
TKMR's Price/Tangible Book is ranked higher than
78% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. TKMR: 4.20 )
TKMR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 177.5
Current: 4.2

0.64
177.5
Price/DCF (Projected) 7.60
TKMR's Price/DCF (Projected) is ranked higher than
91% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: 7.60 )
TKMR' s 10-Year Price/DCF (Projected) Range
Min: 4.67   Max: 7.11
Current: 7.6

4.67
7.11
Price/Median PS Value 7.00
TKMR's Price/Median PS Value is ranked higher than
60% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. TKMR: 7.00 )
TKMR' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 6.53
Current: 7

0.3
6.53
Earnings Yield (Greenblatt) -11.80
TKMR's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. TKMR: -11.80 )
TKMR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.8   Max: 99478.9
Current: -11.8

-11.8
99478.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TKM.Canada, I9DN.Germany,
Tekmira Pharmaceuticals Corp was incorporated on October 6, 2005. The Company develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada. The Company's internal product development candidates include TKM-PLK1, an oncology product candidate that is in Phase I clinical trials to kill cancer cells; and TKM-Ebola, an antiviral product, which is in Phase I of clinical trials for the treatment of the Zaire species of Ebola virus infection. In addition, the Company has licenses from Alnylam targeting two validated oncology targets, WEE1 and CSN5; and to develop TKM-ALDH2, a systemically delivered RNAi therapeutic that utilizes lipid nanoparticle technology for the treatment of alcohol dependence.
» More Articles for TKMR

Headlines

Articles On GuruFocus.com
Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events May 01 2015
Tekmira to Present at Deutsche Bank Health Care Conference May 01 2015
Tekmira to Present at Deutsche Bank Health Care Conference May 01 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events Apr 23 2015
Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results Apr 22 2015
Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results Apr 22 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 22 2015
Tekmira and Collaborators Publish Positive Preclinical Ebola Survival Data in Nature Journal Apr 22 2015
Tekmira and Collaborators Publish Positive Preclinical Ebola Survival Data in Nature Journal Apr 22 2015
Tekmira and Collaborators Publish Positive Preclinical Ebola Survival Data in Nature Journal Apr 22 2015
Tekmira Ebola drug succeeds in small monkey study Apr 22 2015
The Zacks Analyst Blog Highlights: Medicines Co., Tekmira, GW Pharmaceuticals, Biogen and Alexion -... Apr 16 2015
Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label... Apr 15 2015
Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug Apr 14 2015
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog Apr 13 2015
Maxim Analyst Issues Update On Tekmira's Ebola Research Development Apr 13 2015
Tekmira gets nod for more Ebola drug testing Apr 10 2015
Tekmira will resume safety study of Ebola drug within weeks Apr 10 2015
Tekmira will resume safety study of Ebola drug within weeks Apr 10 2015
FDA modifies partial clinical hold on Tekmira Ebola study Apr 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK